While planning to include aromatherapy in patient care, which consideration should a nurse prioritize to ensure patient safety?

Choice A reason: Hypersensitivity reactions and contact dermatitis are significant risks associated with the use of essential oils in clinical settings. Before initiating aromatherapy, the nurse must assess the patient for a history of allergies or atopy. Essential oils contain volatile organic compounds that can trigger bronchospasm or anaphylaxis in susceptible individuals.

Choice B reason: Mixing essential oils with water only is an ineffective method of dilution because oils are hydrophobic and do not dissolve in water. This lack of solubility can lead to uneven distribution, where concentrated droplets of oil come into direct contact with the patient's skin or mucous membranes, potentially causing irritation or chemical burns.

Choice C reason: Utilizing high concentrations of essential oils is contraindicated as it increases the risk of systemic toxicity and localized skin irritation. Therapeutic effectiveness in aromatherapy does not follow a linear dose-response curve where more is better; instead, high concentrations can overwhelm the patient's sensory system and cause adverse physiological responses.

Choice D reason: Applying undiluted essential oils directly to the skin, known as "neat" application, is hazardous and bypasses essential safety testing. Standard nursing practice requires a patch test on a small area of skin to monitor for adverse reactions before broad application, especially in patients with compromised skin integrity or heightened sensitivities.

Choice A reason: Risperidone long-acting injection utilizes microsphere technology that requires a significant lag time for the polymer to degrade and release the active medication. Consequently, therapeutic plasma levels are typically not reached for 3 to 4 weeks, necessitating oral supplementation during the initial induction phase to maintain clinical stability.

Choice B reason: Immediate therapeutic effects are physiologically impossible with depot risperidone formulations due to the slow-release matrix design. Unlike immediate-release aqueous injections used for acute agitation, the depot form is engineered for sustained maintenance therapy and lacks the rapid bioavailability required to produce an instantaneous reduction in psychotic symptoms.

Choice C reason: Full clinical effects are not observed after a single dose because the steady-state concentration of the drug is only achieved after multiple sequential injections. The titration of the medication within the systemic circulation occurs gradually, and clinical improvement is usually assessed over a period of several months.

Choice D reason: The pharmacokinetics of depot risperidone are specifically designed to provide a duration of action far exceeding 24 hours, usually lasting 2 weeks per injection. If the effects dissipated within 1 day, the medication would fail its primary purpose of improving adherence and providing stable neuroleptic coverage.